ISO 18310-2-2021 PDF

ISO 18310-2-2021 PDF

Measurement and prediction of the ambient dose equivalent from patients receiving iodine 131 administration after thyroid ablation-Part 2: External effective dose of the caregivers after release from the hospital

$48.00 $96.00 -50%
Product Code: ISO 18310-2
Stock In Stock
Edition: 1ST
Published: 05/2021
Number of Pages: 20
File Size: 1 file, 1 Byte

Available Options

Product Description

Measurement and prediction of the ambient dose equivalent from patients receiving iodine 131 administration after thyroid ablation — Part 2: External effective dose of the caregivers after release from the hospital

Introduction: ISO 18310 series addresses methods and procedures for measuring ambient dose equivalent from patients administered 131I for thyroid cancer therapy. Thyroid cancer can be treated by administering radioiodine with the remnants after surgery, because radioiodine selectively accumulates in thyroid tissue to irradiate and kill the cancerous cells. Thyroid cancers are small and are not likely to develop into aggressive malignancies. Earlier diagnosis and treatment can remove these cancers at a time when they are not likely to have spread beyond the thyroid gland. There are two common practices for the treatment of thyroid cancer: One is a radioiodine administration without thyroid resection. The other is administration after thyroid resection. In recent years, the radioiodine administration after surgery has become more common as radioiodine selectively accumulates in thyroid tissue to irradiate and kill the cancerous cells. The most commonly used radionuclide for the treatment is 131I. 131I is a radioisotope that emits gamma rays following beta decay. The primary emissions of 131I decay are thus electrons with a maximal energy of 606 keV (89 % abundance, others 248 keV – 807 keV) and 364 keV gamma rays (81 % abundance, others 723 keV). Since the abundance of 364 keV gamma-ray is much greater than other gamma- ray energies, the main contribution to the ambient dose equivalent is from 364 keV gamma-ray. Its radiological half-life is 8,02 d. The iodine is administered orally and is a

Scope: This document addresses the measurement methods, procedures and uncertainty estimation for the measurement, using a personal dosimeter, of the effective dose to the caregiver in the vicinity of the patient treated with radioiodine to ablate the thyroid. The general requirements for the patient and caregiver and a guidance (see Annex A) for designated expert on instructing caregivers of discharged patients is considered to effectively measure the effective dose to the caregiver in the vicinity of the patient.

Be the first to write a review for this product.

Write a review

Note: HTML is not translated!
Bad           Good
ISO 18310-2-2021 PDF

ISO 18310-2-2021 PDF

$48.00 $96.00